CFTR and cystic fibrosis: The study conducted by Steinack et al. found evidence suggesting that the administration of the triple CFTR modulator may be associated with a potential enhancement in glucose tolerance among adult persons diagnosed with CF and possessing at least a single variant of the F508de mutation.